Quarterly ResultMay 5, 2026, 08:02 AM
Cogent Biosciences Plans Dual Bezuclastinib Launches; Q1 Net Loss $97.4M
AI Summary
Cogent Biosciences announced plans for dual launches of bezuclastinib in Systemic Mastocytosis and GIST, highlighting a pivotal year with two NDAs under FDA review and a third expected in the first half of 2026. The company reported a strong cash position of $866.4 million at the end of Q1 2026, providing a runway into 2028. Q1 2026 saw an increased net loss of $97.4 million, driven by higher R&D and G&A expenses as the company advances its pipeline and prepares for commercial launches.
Key Highlights
- Cogent Biosciences plans dual launches of bezuclastinib in Systemic Mastocytosis and GIST.
- Pivotal data from Phase 3 PEAK trial in GIST selected for oral presentation at 2026 ASCO annual meeting.
- Ended Q1 2026 with $866.4 million in cash, sufficient to fund operations into 2028.
- Two NDAs for bezuclastinib are under FDA review, with a third expected in H1 2026.
- FDA accepted NDA for bezuclastinib in NonAdvanced Systemic Mastocytosis with a PDUFA date of December 30, 2026.
- Q1 2026 R&D expenses increased to $75.4 million from $63.0 million in Q1 2025.
- Q1 2026 G&A expenses rose to $28.2 million from $11.9 million in Q1 2025.
- Net loss for Q1 2026 was $97.4 million, compared to a net loss of $72.0 million in Q1 2025.